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Abstract
Duchenne muscular dystrophy is one of the most devastating myopa-
thies. Muscle fibers undergo necrosis and lose their ability to regener-
ate, and this may be related to increased interstitial fibrosis or the
exhaustion of satellite cells. In this study, we used mdx mice, an animal
model of Duchenne muscular dystrophy, to assess whether muscle
fibers lose their ability to regenerate after repeated cycles of degenera-
tion-regeneration and to establish the role of interstitial fibrosis or
exhaustion of satellite cells in this process. Repeated degenerative-
regenerative cycles were induced by the injection of bupivacaine (33
mg/kg), a myotoxic agent. Bupivacaine was injected weekly into the
right tibialis anterior muscle of male, 8-week-old mdx (N = 20) and
C57Bl/10 (control, N = 10) mice for 20 and 50 weeks. Three weeks
after the last injection, the mice were killed and the proportion of
regenerated fibers was counted and reported as a fibrosis index.
Twenty weekly bupivacaine injections did not change the ability of
mdx muscle to regenerate. However, after 50 weekly bupivacaine
injections, there was a significant decrease in the regenerative re-
sponse. There was no correlation between the inability to regenerate
and the increase in interstitial fibrosis. These results show that after
prolonged repeated cycles of degeneration-regeneration, mdx muscle
loses its ability to regenerate because of the exhaustion of satellite
cells, rather than because of an increase in interstitial fibrosis. This
finding may be relevant to cell and gene therapy in the treatment of
Duchenne muscular dystrophy.
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Duchenne muscular dystrophy (DMD),
caused by a defect in the dystrophin gene (1),
is the most common form of muscular dys-
trophy. The absence of dystrophin results in
muscle fiber necrosis which, in the early
stages of the disease, is counterbalanced by
the ability of muscle fibers to regenerate.
The ability to regenerate is subsequently lost
and results in progressive muscle weakness
that usually confines the patient to a wheel-
chair by the early teens and leads to death by
the early twenties (2). Understanding why
muscle loses its ability to regenerate is of
fundamental importance in DMD research
and new insights into the mechanism of im-
paired muscle regeneration can be obtained
by studying the mdx mouse, an animal model
of DMD (3-5).
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The loss of the ability to regenerate may
result from the exhaustion of myogenic sat-
ellite cells caused by excessive cycles of
degeneration and regeneration (6-8). How-
ever, no decline in muscle regeneration was
reported in mdx mice when the muscle was
subjected to repeated cycles of degeneration
and regeneration (9), and there is no evi-
dence that extensive myoblast proliferation
depletes the myogenic responsiveness in later
life when the animals become weak and
wasted. The loss of regenerative capacity
could also result from a progressive increase
in muscle interstitial fibrosis since this would
prevent the movement of myogenic cells,
which is necessary for myotube formation
(7,8). The role of fibrosis has not been well
established nor is it clear why the capacity
for regeneration declines in DMD and in
mdx mice.
In this study, we examined whether the
ability of mdx muscle to regenerate decreases
after a prolonged period of repeated cycles
of degeneration-regeneration, and whether
this reduction was related to the exhaustion
of satellite cells or to an increase in intersti-
tial fibrosis. Our results provide a long-term
in vivo analysis of the decline in the regen-
erative ability of muscle.
Cycles of degeneration and regeneration
were induced by intramuscular injections of
5 mg/ml bupivacaine hydrochloride to pro-
vide a dose of 33 mg/kg. All experiments
were done in accordance with the guidelines
for the use of animals set forth by our institu-
tion. Twenty male mdx mice were anesthe-
tized with a mixture of ketamine hydrochlo-
ride and thiazine hydrochloride (0.01 ml and
0.02 g/ml, ip) and 0.2 ml bupivacaine was
injected into the upper two thirds of the right
tibialis anterior muscle. Contralateral muscles
were injected with 0.2 ml sterile physiologi-
cal saline. The first injection was given 8
weeks after birth. Thereafter, the animals
received weekly injections for 20 weeks (N
= 10) and 50 weeks (N = 10). Ten C57Bl/10
mice (controls) received the same treatment.
The mice in each group were killed 3
weeks after the last injection for each period,
and fixed in formol-calcium fixative for 24
h. The mice were killed with an overdose of
the anesthetic after removal of the muscles.
After fixation, the muscles were processed
for embedding in hydroxyethyl methacrylate
and 2-µm transverse sections obtained from
the middle muscle belly were stained with
hematoxylin and eosin.
The total cross-sectional area (TCSA),
defined as the area occupied by the myofibers
plus connective tissue, was measured in a
single complete section of individual muscle
using a 40X objective and a computer-as-
sisted image analyzer system. The cross-
sectional area of each myofiber (myofiber
cross-sectional area, MCSA) was measured
and the sum of all MCSA was considered to
be the total myofiber cross-sectional area
(TMCSA). The area of interstitial fibrosis
(AIF) was then calculated by subtracting the
total myofiber cross-sectional area from the
total cross-sectional area (AIF = TCSA -
TMCSA). The number of muscle fibers was
counted on a video monitor. In the mdx mice
at the age studied, as well as in the C57Bl/10
control mice treated with bupivacaine, al-
most all of the fibers were regenerated, which
is in agreement with earlier reports for mdx
(3) and after bupivacaine injections (10).
One group of 10 mdx mice received no
bupivacaine or saline injections (untreated
group). These mice were killed as described
above at 31 and 61 weeks and the right
tibialis anterior muscles were processed and
examined as described for treated muscles.
The data for bupivacaine-injected, saline-
injected and untreated muscles from mdx
mice and untreated muscles from C57Bl/10
mice were analyzed statistically using the
unpaired Student t-test.
After 20 injections of bupivacaine, the
muscle fiber population was not different
from that observed in age-matched untreated
(31 weeks old) mdx or saline-injected mdx
mice. However, after 50 bupivacaine injec-
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tions, the muscle fiber population decreased
significantly (Table 1). This finding demon-
strated that muscle regeneration depended
on the number of injections and, therefore,
on the number of degeneration-regeneration
cycles to which muscle fibers were exposed.
The observation that the regenerative capac-
ity of mdx muscle was not affected by re-
peated bupivacaine injections (9) may be
explained by the lower number of injections
used in the latter study.
No decrease in the muscle fiber popula-
tion was observed in mdx mice after 20
bupivacaine injections, despite a significant
increase in the area of interstitial fibrosis,
when bupivacaine-injected mdx muscles (20
injections) were compared with nontreated,
age-matched mdx muscles (Table 1). The
increase in the area of interstitial fibrosis
concomitant with an increase in the total
cross-sectional area of the muscle is well
correlated to the phenomenon of pseudo-
hypertrophy, classically described for DMD
(2). On the other hand, the muscle fiber
population decreased dramatically after 50
bupivacaine injections, but without a signifi-
cant increase in the area of interstitial fibro-
sis when compared to muscles receiving 20
bupivacaine injections (Table 1, Figure 1).
These findings demonstrate that there was
no direct correlation between the increase in
interstitial fibrosis and the impairment of
muscle regeneration. They also suggest that
the loss of regenerative ability was related to
the exhaustion of myogenic cells rather than
to an increase in interstitial fibrosis in mdx.
The gradual increase in interstitial fibrosis as
a result of repeated cycles of degeneration-
regeneration would prevent the movement
of myogenic cells required for myotube for-
mation (7,8). However, our results support
previous studies suggesting that an increase
in interstitial fibrosis does not play a central
role in the loss of regenerative ability. When
mdx muscles were treated with a single in-
jection of notexin, a potent myonecrotic
agent, there was an increase in interstitial
Table 1. Total muscle fiber population, total cross-sectional area (TCSA), total myofiber
cross-sectional area (TMCSA) and the area of interstitial fibrosis (AIF) in non-injected
and bupivacaine (BPVC)-treated C57Bl/10 and mdx muscles.
C57Bl/10 mdx
Non-injected BPVC Non-injected Saline BPVC
31 61 20 50 31 61 20 50 20 50
Total muscle 4589 4627 4649 4619 4446 4639 4672 4717 4507 3323*
fiber population
TCSA (mm2) 2.56 2.59 2.57 2.58 2.53 2.59 2.56 2.62 2.73 2.42*
TMCSA (mm2) 2.24 2.26 2.25 2.17 2.21 2.16 2.25 2.15 2.02 1.70*
AIF (mm2) 0.32 0.33 0.32 0.41 0.32 0.43 0.31 0.46 0.71* 0.72*
Non-injected mice were killed at the same age (31 and 61 weeks) as the injected mice
(20 and 50 injections).
*P<0.05 compared to saline- and non-injected mdx muscle (Student t-test).
Figure 1. mdx regenerated
muscle fibers with central cell
nuclei after 20 (A) and 50 (B)
bupivacaine injections. Hema-
toxylin and eosin (bars = 150
µm).
fibrosis with no change in the muscle fiber
population (11). Despite the progressive fi-
brosis that occurs during the natural course
of the disease, muscle recovery is better in
young mdx mice than in a control mouse
strain (12).
The observation that bupivacaine-injected
mdx fibers lose their ability to regenerate,
A
B
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whereas bupivacaine-injected C57Bl/10
muscles do not, supports the recent sugges-
tion that in mdx mice a lineage of myogenic
cells, which is responsible for muscle repair
after extreme damage, is eliminated during
the course of the disease (6). We assumed
that the impairment of muscle regeneration
in mdx mice probably resulted from the ex-
haustion of this cell lineage since bupiva-
caine is a potent myotoxic agent and spares
single cells, including satellite cells. If true,
the present in vivo technique should allow us
to estimate how many degenerative-regen-
erative cycles this subset of cells undergoes
before exhaustion. We propose that after 20
repeated injections of bupivacaine, each
muscle fiber presumably underwent at least
14 cycles of degeneration and regeneration,
while after 50 injections, it underwent 35
cycles (13). Considering that each cycle in-
volves four doublings of myogenic cells (14),
we estimated that these cells would undergo
a total of 56 doublings in the 20 bupivacaine
group and 140 doublings in the 50 bupiva-
caine group.
The observation that interstitial fibrosis
cannot account for the loss of regenerative
ability has important clinical implications
and may have applications in therapies for
DMD. Since there is currently no cure for
DMD, and since DMD cannot be eliminated
by genetic counseling, cell and genetic thera-
pies, such as myoblast transfer, have been
explored as possible solutions. This approach
involves the delivery of exogenous myo-
blasts which have to survive the normal im-
mune rejection and migrate away between
existing muscle fibers in order to form new
fibers and to fuse with the host dystrophic
fibers. However, experimental studies and
clinical trials with this approach have met
with little success (15), and there is consid-
erable uncertainty as to whether this failure
is the result of rejection of the transplanted
cells or is due to the limited migration of
implanted cells imposed by scar tissue. Since
increased interstitial fibrosis is not related to
the absence of muscle regeneration, immu-
nological aspects should be given more con-
sideration, including the insertion of copies
of the missing gene using adeno-associated
virus vectors (16,17) or the use of new
immunosuppressor schedules (18), rather
than trying to improve myoblast dispersion
(19). This view is supported by recent find-
ings showing that dystrophin expression in
mdx mice is restored by the intravenous in-
jection of stem cells which need to diffuse
along host dystrophic and normal muscle
fibers (20).
The ability of muscle to regenerate is lost
in mdx mice after prolonged degenerative-
regenerative cycles. This impairment is re-
lated to the exhaustion of myogenic cells
rather than to an increase in scar tissue. Our
results support the idea that a subset of pro-
liferative myogenic cells that can be evoked
by extreme conditions of muscle damage is
impaired in mdx, but not in normal mice.
These cells may have a life span greater than
56 doublings. These results may have impli-
cations for therapeutic interventions in DMD
involving genetic engineering and myoblast
implantation.
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